Why should an asthma patient never use a LABA alone?

• A. Causes tachycardia
• B. No effect on inflammation
• C. Mortality risk
• D. Only used in COPD

Answer: (C)

In asthma, addressing airway inflammation is essential, not just opening the airways. Long-acting beta-agonists (LABAs) relax smooth muscle and provide long-lasting bronchodilation, but they do not reduce the underlying inflammation driving the disease.

Using a LABA alone has been linked to an increased risk of asthma-related severe events and death in clinical studies, which is why safety guidelines require LABAs to be used only in combination with an inhaled corticosteroid that tackles inflammation. This combination controls both the airflow limitation and the inflammatory process, lowering the risk of fatal exacerbations. Tachycardia can occur with LABAs, and while LABAs lack anti-inflammatory action, the critical risk prompting their combined use is the mortality risk. LABAs are not exclusive to COPD; they’re used in asthma only as part of an anti-inflammatory regimen.